Does rosuvastatin cause hair loss? This is a question many patients ask after noticing increased hair shedding whilst taking this widely prescribed cholesterol-lowering medication. Rosuvastatin is a potent statin used across the UK to reduce LDL cholesterol and lower the risk of heart attack and stroke. Whilst alopecia is listed as a rare adverse effect in rosuvastatin's UK Summary of Product Characteristics, the evidence linking it directly to hair loss is limited, based largely on spontaneous case reports rather than clinical trial data. This article examines what the evidence shows, other potential causes to consider, and what to do if you are concerned.

Rosuvastatin and Hair Loss: What the Evidence Shows

Alopecia is listed as a rare adverse effect in rosuvastatin's UK SmPC, but evidence is based on spontaneous case reports rather than controlled trials, and no causal mechanism has been confirmed.

Experiencing these side effects? Our pharmacists can help you navigate them →

Rosuvastatin is a potent statin medication widely prescribed in the UK to lower LDL cholesterol and reduce the risk of cardiovascular events such as heart attack and stroke. It works by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. Whilst rosuvastatin is generally well tolerated, patients sometimes report hair thinning or hair loss and wonder whether their medication is to blame.

Hair loss (alopecia) is listed as an adverse effect of rosuvastatin in its UK Summary of Product Characteristics (SmPC), available via the Electronic Medicines Compendium (EMC). The frequency is categorised as 'rare' (affecting fewer than 1 in 1,000 users) or, in some post-marketing sections, as 'frequency not known' — reflecting that the evidence comes largely from spontaneous reports rather than controlled trials. It is important to note that adverse effect listings and their assigned frequencies differ between individual statins; readers should refer to the SmPC for their specific medicine rather than assuming a uniform class effect.

The evidence directly linking rosuvastatin to hair loss is limited and is based primarily on isolated case reports and spontaneous post-marketing reports rather than robust clinical trial data. Spontaneous case reports cannot establish causality — they indicate a possible association but do not confirm that the drug caused the effect. No well-established causal mechanism has been identified.

It is also important to recognise that correlation does not equal causation. Many people who begin taking rosuvastatin are in middle age or older — a life stage when hair thinning naturally becomes more common for both men and women. Attributing hair changes solely to the medication without ruling out other causes can lead to unnecessary anxiety or, more seriously, discontinuation of a clinically important treatment. If you have concerns, speaking with your GP or pharmacist before making any changes to your medication is strongly advised.

How Common Is Hair Loss as a Side Effect of Statins?

Across all statins, alopecia is consistently classified as rare in regulatory documentation; large-scale trials such as JUPITER did not identify hair loss as a statistically significant adverse event.

Not sure if this is normal? Chat with one of our pharmacists →

Across the statin class — which includes atorvastatin, simvastatin, pravastatin, and rosuvastatin — alopecia is consistently classified as a rare adverse effect in regulatory documentation, though the precise frequency category varies by individual drug and SmPC. Readers should consult the BNF or the relevant SmPC for their specific statin.

Large-scale clinical trials such as the JUPITER trial (Ridker et al., NEJM 2008), which specifically evaluated rosuvastatin 20 mg versus placebo in nearly 18,000 participants, did not identify hair loss as a statistically significant adverse event. This suggests that, at a population level, any risk is very low — though it should be noted that alopecia was not a pre-specified endpoint in that trial.

Post-marketing surveillance data submitted to the MHRA's Yellow Card scheme does include occasional reports of hair loss associated with statin use. However, it is important to understand that spontaneous Yellow Card reports are used for signal detection — they cannot be used to calculate the incidence of a side effect or to prove that a drug caused a particular reaction. The absolute number of reports remains small relative to the millions of statin prescriptions issued annually in England.

When hair loss does occur in statin users, it most commonly presents as:

• Diffuse thinning across the scalp rather than patchy loss, consistent with a telogen effluvium pattern

• Gradual onset, often noticed weeks to months after starting treatment

• Mild to moderate severity, which may stabilise over time

It is worth emphasising that the cardiovascular benefits of rosuvastatin — including significant reductions in major adverse cardiac events — are well evidenced and endorsed by NICE guideline NG238 (Cardiovascular disease: risk assessment and reduction, including lipid modification, 2023). For the vast majority of patients, the benefit-to-risk profile strongly favours continuing treatment, and hair loss alone is rarely a sufficient clinical reason to stop a statin without medical review.

Other Medications and Conditions That Can Cause Hair Loss

Thyroid disorders, iron deficiency, androgenetic alopecia, and telogen effluvium are among the most common causes of hair loss and should be excluded before attributing thinning to rosuvastatin.

Before attributing hair thinning to rosuvastatin, it is essential to consider the wide range of other medications and underlying health conditions that are far more commonly associated with alopecia. This is particularly important because many patients taking statins are also managing multiple conditions and may be prescribed several medicines simultaneously.

Common medical causes of hair loss include:

• Thyroid disorders — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning; coexisting thyroid disease is common and should be excluded early

• Iron deficiency — a frequently overlooked cause, especially in women of reproductive age

• Androgenetic alopecia — the most common form of hair loss in both men and women, driven by genetic and hormonal factors

• Telogen effluvium — a temporary shedding typically beginning 2–3 months after a physical or emotional trigger such as illness, surgery, significant weight change, or psychological stress, and which may take several months to improve once the underlying cause is addressed

• Autoimmune conditions — such as alopecia areata or lupus

Medications more commonly associated with hair loss include (as listed in BNF monographs and NHS guidance):

• Anticoagulants (e.g., warfarin, heparin)

• Antithyroid drugs (e.g., carbimazole)

• Antidepressants (e.g., fluoxetine, sertraline)

• Hormonal contraceptives

• Retinoids

• Certain antihypertensives (e.g., beta-blockers)

The strength of evidence for hair loss varies between these agents; your GP or pharmacist can advise on your specific medicines.

A thorough medication review and clinical assessment are therefore necessary before concluding that rosuvastatin is responsible. In line with NICE CKS and primary care guidance, your GP will typically arrange first-line blood tests including thyroid-stimulating hormone (TSH), full blood count (FBC), and serum ferritin. Further investigations — such as vitamin B12, vitamin D, zinc, or thyroid antibodies — will only be requested if clinically indicated based on your history and examination findings. Addressing a treatable underlying cause often leads to significant improvement in hair health without any need to alter cardiovascular medication.

What to Do If You Notice Hair Thinning While Taking Rosuvastatin

Do not stop rosuvastatin without speaking to your GP first; book an appointment, keep a record of symptoms, and request first-line blood tests including TSH, FBC, and ferritin.

If you notice increased hair shedding or thinning after starting rosuvastatin, it is understandable to feel concerned. However, it is important to approach this methodically rather than stopping your medication abruptly, as doing so without medical guidance could increase your cardiovascular risk.

Practical steps to take:

• Do not stop rosuvastatin without speaking to your GP or pharmacist first. Abrupt discontinuation of a statin in high-risk patients can have serious consequences.

• Keep a record of when the hair loss started, its pattern, and any other new symptoms (e.g., fatigue, weight changes, skin changes), as this information will help your clinician assess the cause.

• Book a GP appointment to discuss your concerns. Your doctor will take a full history, review your complete medication list, and arrange appropriate investigations.

• Request first-line blood tests — TSH, FBC, and ferritin — with further tests only if clinically indicated.

Seek prompt GP review or ask about dermatology referral if you notice any of the following red flags:

• Sudden or rapidly progressive patchy hair loss

• Loss of eyebrows or eyelashes

• Scalp redness, scaling, pustules, pain, or tenderness (which may suggest scarring alopecia requiring urgent assessment)

• Associated systemic symptoms such as joint pain, rash, or significant fatigue

During your consultation, your GP will assess the pattern of hair loss. Diffuse thinning is more suggestive of a systemic, nutritional, or telogen effluvium cause, whilst patchy loss or inflammatory scalp signs may indicate an autoimmune process requiring dermatological referral. If no other cause is identified and there is a clear temporal relationship between starting rosuvastatin and hair loss, your doctor may — in line with the shared decision-making principles set out in NICE NG238 — consider a supervised trial of switching to an alternative statin to observe whether the hair loss resolves. This decision should always be balanced against your individual cardiovascular risk profile.

In the meantime, gentle hair care practices — avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments — can help minimise further mechanical hair loss whilst investigations are under way.

If you believe rosuvastatin or any other medicine has caused a side effect, you or your healthcare professional can report this via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. These reports contribute to ongoing pharmacovigilance and help regulators identify emerging safety signals, even when causality is uncertain.

Stopping or Switching Statins: What NICE and MHRA Guidance Says

NICE NG238 advises against discontinuing statins without careful clinical consideration; if rosuvastatin is suspected, options include switching statin, dose reduction, or supervised discontinuation under medical supervision.

NICE guideline NG238 (Cardiovascular disease: risk assessment and reduction, including lipid modification, 2023) provides clear recommendations on the use of statins for primary and secondary prevention of cardiovascular disease. The guidance emphasises that statins should not be discontinued without careful clinical consideration, particularly in patients with established cardiovascular disease or high 10-year cardiovascular risk, where the evidence of benefit is strongest. NG238 also sets out a shared decision-making framework for managing statin intolerance and adverse effects, which applies equally to hair loss.

If, following thorough investigation, a clinician and patient jointly decide that rosuvastatin may be contributing to hair loss, options supported by NICE NG238 may include:

• Switching to an alternative statin (e.g., atorvastatin or pravastatin) at an equivalent therapeutic dose, to assess whether the side effect is drug-specific or class-related

• Dose reduction, if clinically appropriate and lipid targets can still be met

• Temporary supervised discontinuation with close monitoring of lipid levels and cardiovascular risk markers

For patients with complex statin intolerance or where maintaining adequate cardiovascular risk reduction is challenging, referral to a specialist lipid clinic or secondary care may be appropriate.

It is worth noting that there is no specific NICE or MHRA guidance recommending statin discontinuation for hair loss, reflecting the rarity and generally mild nature of this side effect. Any decision to alter treatment should be made collaboratively between the patient and their prescriber, weighing the modest and uncertain risk of hair loss against the well-evidenced cardiovascular benefits of continued statin therapy.

Suspected adverse drug reactions — including hair loss — should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). This reporting supports ongoing pharmacovigilance; however, as noted above, spontaneous reports are used for signal detection and cannot be used to determine the incidence of a side effect or confirm causality. Patients and healthcare professionals alike are encouraged to submit reports even when causality is uncertain.

Frequently Asked Questions